[cAMP] i have been suggested as potential therapeutic options for the treatment of CF (31). 48
Cyclic nucleotide phosphodiesterases (PDEs) terminate signalling by hydrolyzing cyclic 49 nucleotides (7). The PDE superfamily includes 11 gene families and over 30 isozymes, each 50 with multiple splice variants that together comprise almost 100 different variants (42) . 51
Expression and localization of PDE isoenzymes is cell and tissue specific and many PDEs are 52 often expressed in specific microdomains which allow for highly organized spatio-temporal 53 cyclic nucleotide signalling. For detailed reviews of PDEs see Conti and Beavo (14) , Francis 54 et al. (21) and Maurice et al. (42) . 55 PDE3 and PDE4 have been shown to regulate CFTR in primary airway epithelial cells and in 56 epithelial cell lines. PDE4A5, PDE4C1, PDE4D2, and PDE4D3 expression was demonstrated 57 in primary human airway epithelial cells (22) and PDE3 and PDE4 inhibitors have been 58
shown to elevate [cAMP] i in airway epithelia, when added alone (12) or in combination with 59 activators of adenylyl cyclase (22, 65) . Furthermore, both PDE3 and PDE4 inhibitors have 60 been shown to activate CFTR-dependent anion secretion across the human airway epithelial 61 cell line 48) while Barnes et al. (4) demonstrated increased CFTR channel 62 activity when apical membrane patches excised from Calu-3 cells were exposed to a PDE4 63 inhibitor. CFTR can interact physically with PDE4D (38) and PDE3A (48) and exposure to a 64 PDE3A inhibitor leads to clustering of CFTR and PDE3A into membrane microdomains and 65 augments CFTR channel function (48). These results suggest that inhibitors of PDE3 and 66 PDE4 could potentially be useful therapeutics for CF. 67
More recently, Blanchard et al. (6) demonstrated that the PDE4 inhibitor rolipram, when used 68 in combination with CFTR potentiators and correctors, stimulates CFTR activity in primary 69 human bronchial epithelial (HBE) cells homozygous for the most common CF mutation 70
F508del (10). In addition to their CFTR-activating properties, PDE3 and 4 inhibitors also 71 have beneficial anti-inflammatory and bronchodilator effects, which would provide additional 72 benefits to CF patients. Di Paola et al. (19) demonstrated PDE3 inhibition significantly 73 reduced tissue inflammation and the release of pro-inflammatory cytokines in a rat model of 74 myocardial inflammation while PDE4 inhibition has also been shown to reduce the release of 75 pro-inflammatory cytokines from a number of cell types, including airway epithelial cells, as 76 well as suppressing recruitment of inflammatory cells to the airways (24-26, 37, 40, 45, 68) . 77
Of further interest, there is increasing evidence to suggest that dual inhibition of PDE3 and 78 PDE4 can have additive or synergistic anti-inflammatory, bronchodilator and CFTR 79 activating effects (1, 39, 44, 48) suggesting that targeting both PDEs may be of greater 80 benefit than inhibiting one alone. RPL554 is a "first in class" inhaled dual PDE3/4 inhibitor 81 which has significant bronchodilator and anti-inflammatory activity in clinical trials (20) . 82 RPL554 has been demonstrated to induce sustained relaxant effects on contractile responses 83 induced by spasmogens (histamine and carbachol) and electrical field stimulation (EFS) in 84 isolated airway tissue (human bronchial and guinea pig tracheal preparations). The degree of 85 bronchial wall relaxation was greater than in tissue treated only with a β 2 agonist or anti-86 muscarinics, even when those agents were administered at maximal concentrations (9) . 87 Interestingly RPL554 also interacts in an additive or synergistic manner with β 2 agonists or 88 anti-muscarinics respectively when administered in combination in in vitro and in vivo 89 experimental model systems (8, 30) . The fact that RPL554 inhibits PDEs involved in CFTR 90 regulation, as well as possessing anti-inflammatory and bronchodilator properties, suggests it 91 could afford therepaeutic benefit in CF patients. PDE inhibitors may also act on airway cilia 92 since their motility is also controlled by cAMP/PKA (2, 18, 55, 63) probably through 93 phosphorylation of dynein light chain in the axoneme (36) Indeed, the PDE4-selective 94 inhibitor, Roflimulast N-oxide, increased ciliary beat frequency (CBF) in human bronchial 95 epithelia (43) . 96
The purpose of this study was to examine the effect of RPL554 on CFTR function in cell 97 lines and primary human bronchial epithelia (HBE) from CF patients with R117H/F508del 98 and F508del/F508del genotypes. R117H reduces single channel conductance and open 99 probability but does not affect trafficking to the plasma membrane or activation by 100 cAMP/PKA (11, 57, 62) . F508del reduces open probability and nearly abolishes trafficking 101 to the plasma membrane without altering single channel conductance (10, 15). We also 102 examined the effect of RPL554 on ciliary beating. Here we show that RPL554 stimulates the 103 activity of WT and R117H CFTR, and this is primarily due to inhibition of PDE4. RPL554 104 also increases ciliary beat frequency primarily through inhibition of PDE4. These results 105 suggest RPL554 as an attractive therapeutic option for CF and reveal novel mechanisms by 106 which inhaled RPL554 may improve lung function in COPD and asthma patients. Therefore, although RPL554 failed to stimulate CFTR activity alone, the fact it could 219 enhance forksolin-stimulated CFTR activity to such an extent indicates its potential to 220 enhance CFTR activity. 221
RPL554 acts as a CFTR activator in CFBEwt cells: We next examined whether 222
RPL554 was able to activate wtCFTR in the human airway epithelial cell line CFBE. 223 RPL554 dose-dependently increased CFTR-dependent I sc with the highest concentration of 224 RPL554 tested (10 μM) increasing I sc by 49.8 ± 7.8 μA cm -2 (n=4). For comparison this was 225 57.6 ± 3.8% of the stimulation produced by a maximal (10 μM) concentration of forskolin 226 (86.5 ± 12.0 μA cm -2 , n=5; Fig. 2 ). Therefore, these data suggested that RPL554, via 227 inhibition of PDE3 and/or PDE4, raised [cAMP] i levels sufficiently to activate CFTR-228 dependent transepithelial anion secretion to levels that are comparable with those produced 229 by forskolin. Thus RPL554 activates robust secretion by this human airway cell line in the 230 absence of other secretagogues. 231
PDE expression is altered in CF pHBE cells compared to WT pHBE cells: RPL554 is 232
a dual PDE3/4 inhibitor, therefore we examined the expression of these PDE isoenzymes, 233 together with other PDE isoforms as well as examining whether their expression was altered 234 in CF. Expression of a subset of eight known PDE isoforms was assessed in HBE cells from 235 three non-CF donors, three patients homozygous for F508del, and three patients carrying 236 R117H/F508del. By assessing the relative expression of each PDE gene tested when 237 normalizing to the expression of GAPDH, we were able to get an indication of which PDE 238 genes were most abundantly expressed in HBE cells. As shown in figure 3A , PDE4D was 239 expressed in relatively high abundance in WT cells which is unsurprising given the body of 240 evidence implicating PDE4D in CFTR regulation in human airway epithelia. However, there 241 was a very low expression of PDE3A when normalized to GAPDH expression across all 242 three genotypes, indicating PDE3A is expressed at very low levels in HBE cells relative to 243 other PDE isoforms. An unexpected finding was the abundance of PDE7A and PDE8A 244 expression in all three genotypes, raising the question as to their role in cyclic nucleotide 245 signalling in human airway epithelia. When normalizing the PDE gene expression relative to 246 the WT patients, we observed a 5.1 ± 2.3 fold upregulation of PDE3A and a 3.9 ± 1.9 fold 247 upregulation of PDE4D in F508del/F508del cells compared to WT (p<0.001 vs. WT; n=3 for 248 each; Fig. 3B ) which suggests a loss of CFTR at the cell surface may modulate expression of 249 proteins involved in CFTR regulation. 250
PDE inhibition does not stimulate CFTR-dependent transepithelial ion transport in 251

HBE F508del/F508del cells but increases the response to VX-770: To assess whether (i) 252
RPL554 had similar CFTR stimulatory effects in HBE cells as those observed in CFBE cells 253 and (ii) RPL554 was able to potentiate the activity of mutant CFTR, the effect of RPL554 254 was tested in F508del/F508del HBE cells. To gain insight into the mechanism of action, the 255 effects of RPL554 were also compared with those of the PDE3-selective inhibitor milrinone 256 and the PDE4-selective inhibitor rolipram. Cells were pre-treated for 24 hours with VX-809 257
(1 μM) and VX-770 (100 nM) to mimic the current treatment for F508del/F508del patients. 258
A submaximal concentration of forskolin (2 μM) stimulated an increase in I sc of 2.9 ± 0.3 μA 259 cm -2 (n=25; Fig. 4 ). However, subsequent exposure to specific PDE inhibitors did not further 260 enhance I sc and actually caused a small decrease in CFTR-dependent I sc . PDE-stimulated 261 increases in I sc after forskolin stimulation were -0.3 ± 0.1 μA cm -2 , -0.3 ± 0.1 μA cm -2 , -1.0 ± 262 0.4 μA cm -2 and -0.1 ± 0.1 μA cm -2 by milrinone (10 μM), rolipram (10 μM), milrinone + 263 rolipram and RPL554 (10 μM) respectively (n=5-7; Fig. 4 ). These results suggest that 264
F508del CFTR at the membrane was fully activated by forskolin following rescue by the 265 corrector VX-809 and chronic potentiation by VX-770 and thus any subsequent increases in 266 cAMP were unable to further stimulate CFTR-dependent anion transport. We also 267 investigated whether PDE inhibition could stimulate F508del CFTR in non-corrected cells 268 Forskolin stimulated a larger increase in CFTR-dependent I sc (1.4 ± 0.1 μA cm -2 ; n=16), 310 compared to that induced by apical adenosine (0.2 ± 0.2 μA cm -2 ; p<0.001; n=6; Fig 8A) . 311
However, the subsequent response to PDE inhibitors was similar in cells stimulated with 312 either agonist. Milrinone + rolipram increased I sc by 0.6 ± 0.1 μA cm -2 and 0.8 ± 0.3 μA cm -2 313 after pre-treatment with forskolin and adenosine, respectively (p>0.05; n=3-9; Fig. 8B ), and 314 RPL554 increased I sc by 0.9 ± 0.2 μA cm -2 and 0.7 ± 0.2 μA cm -2 , respectively (p>0.05; n=3-315 9; Fig. 8B ). Together, these data imply that PDE regulation occurs predominantly in the sub-316 apical cAMP compartment in HBE R117H/F508del cells. 317
VX-770 and RPL554 have additive effects on CFTR-dependent anion transport: 318
Given that we have already shown that PDE inhibition enhances CFTR activity in 319 R117H/F508del HBE cells, it was interesting to test the effect of PDE inhibition in 320 combination with the clinically-approved CFTR potentiator VX-770 (Kalydeco). To this end, 321 R117H/F508del cells were stimulated with 2 μM forskolin and then treated with either 10 μM 322 RPL554 followed by 100 nM VX-770 (Fig. 9A , left panel) or in reverse order; i.e. 100 nM 323 VX-770 followed by 10 μM RPL554 (Fig. 9A, right panel) . RPL554 further increased the 324 forskolin-stimulated CFTR-dependent I sc by 2.4 ± 0.2 μA cm -2 (n=4) and the subsequent 325 addition of VX-770 caused a further increase of 6.2 ± 0.3 μA cm -2 . The net increase in 326 CFTR-dependent I sc under these conditions (8.6 ± 0.6 μA cm -2 ) was significantly greater than 327 when either agonist was added alone (p<0.01; n=3; Fig. 9B ). Adding VX-770 after forskolin 328 stimulation caused I sc to increase by 4.3 ± 0.5 μA cm -2 (n=17) However, subsequent addition 329 of RPL554 failed to increase CFTR activity further and the total stimulation was only about 330 half that when RPL554 was added first. These data indicate that larger responses are obtained 331 with these agents in combination; however the enhanced response depends on the order of 332 exposure. Thus a combination therapy involving VX-770 and RPL554 could provide 333 additional benefits to R117H/F508del patients although this may depend on their order of 334 administration and pharmacokinetics. 335
Exposure of R117H/F508del HBE cells to pro-inflammatory cytokines does not alter 336 the effect of PDE inhibition on CFTR-dependent I sc :
In an attempt to mimic the 337 pathophysiological state of CF airways, R117H/F508 HBE cells were treated with the pro-338 inflammatory cytokine TNF-α (1 ng/ml) for 24 h prior to assessing the CFTR-dependent I sc in 339 response to PDE3/4 inhibition. Pre-treatment with TNF-α did not significantly alter the 340 response to PDE inhibition after pre-stimulation with submaximal forskolin (2 μM); 341 milrinone stimulation was negligible in control cells (0.3 ± 0.2 μA cm -2 ; n=3) and in TNF-α-342 treated cells (-0.01 ± 0.02 μA cm -2 ; p>0.05 vs. control; n=3; Fig. 10 ), demonstrating that 343 PDE3 inhibition does not modulate CFTR activity, even when cells are in a pro-inflammatory 344 state. Similarly, in cells that had been pre-treated with TNF-α and stimulated with forskolin, 345 there was no increase (p>0.05; n=3) in the I sc response to rolipram (2.6 ± 0.1 μA cm -2 vs. 1.9 346 ± 0.4μA cm -2 ), milrinone + rolipram (2.0 ± 0.4μA cm -2 vs. 2.2 ± 0.1μA cm -2 ) and RPL554 347 (1.5 ± 0.4μA cm -2 vs. 1.7 ± 0.3μA cm -2 ) when compared with control cells (Fig. 10) . 348
RPL554 increases ciliary beat frequency in HBE cells: In addition to CFTR-349 dependent anion secretion, mucocilary clearance depends on ciliary beating -a process which 350
is also regulated by cAMP signalling (2, 18, 36, 55, 63) . We therefore measured ciliary beat 351 frequency (CBF) in WT HBE cells to assess whether it is increased by RPL554. Treatment of 352 cells with RPL554 for 30 mins significantly increased CBF by 2.6 ± 0.8% at 1 minute post 353 treatment when compared to time-matched DMSO controls (p<0.05; n=11), 8.1 ± 1.2% at 5 354 mins post treatment (p<0.001; n=11) and 10.4 ± 1.8% at 30 mins post treatment (p<0.001; 355 n=11; Fig. 11 ). The effect of RPL554 was almost identical to that of the selective PDE4 356 inhibitor roflumilast (Fig. 11) , providing evidence that RPL554 increases ciliary beating and 357 therefore is predicted to promote mucociliary clearance in both WT and CF patients. 358
Discussion: 359
By inhibiting phosphodiesterase-dependent breakdown of cAMP, PDE3 and PDE4 360 inhibitors have previously been shown to stimulate CFTR in human airway epithelial cells, 361 suggesting they could be a therapeutic option for the treatment of CF. Here, we investigated 362 the effect of RPL544, a dual PDE3/4 inhibitor which has bronchodilator effects in asthma and 363 COPD patients (20), for its ability to restore CFTR function in several cell types, including 364 primary human bronchial epithelia. Firstly, we demonstrated that although RPL554 was not 365 able to stimulate CFTR in CHO cells, indicative of low basal adenylyl cyclase activity, it was 366 able to potentiate CFTR activity when cells were stimulated by a submaximal concentration 367 of forskolin (Fig. 1) . These findings imply that inhibition of PDE3 and 4 in CHO cells 368 enhanced the increase in [cAMP] i after forskolin stimulation sufficiently to further stimulate 369 CFTR. By contrast, RPL554 did stimulate CFTR in the bronchial epithelial cell line CFBE 370 under basal conditions in a dose-dependent manner (Fig. 2) . Although the highest 371 concentration of RPL554 tested was less potent than forskolin, PDE3/4 inhibition was clearly 372 able to raise [cAMP] i sufficiently to activate CFTR. These results with CFBE cells are similar 373 to those reported for the airway cell line Calu-3 in which PDE3 and PDE4 inhibitors induced 374 10-85% of the forskolin response (12). More specifically, given that PDE4D has been shown 375 to be involved in cAMP compartmentalization (4) suggests that the effects of RPL554 may be 376 mediated by increased cAMP levels within the CFTR microdomain which depends on 377 transmembrane adenylyl cyclase (tmAC) activity. The distinct effects of RPL554 in CHO and 378 CFBE cells suggest CFBE cells have much higher basal tmAC activity and consequentially 379 cAMP turnover and highlight the cell-type specific effects of RPL554. 380
We next compared the effects of the dual PDE3/4 inhibitor RPL554 with those of the 381
PDE3 selective inhibitor (milrinone) and the PDE4 selective inhibitor (rolipram). CFTR-382 dependent anion transport was measured in primary HBE cells from CF patients carrying 383
F508del/ΔF508del or R117H/F508del alleles. qPCR results revealed upregulation of PDE3 384 and PDE4D expression in CF cells when compared with WT cells but the overall level of 385 PDE3 expression was very low compared to PDE4D and, interestingly, PDE7A and PDE8A 386 (Fig. 3) . In F508del/F508del cells pre-treated with VX-770 and VX-809, forskolin stimulated 387 CFTR-dependent I sc ; however, PDE inhibitors did not cause further I sc increases suggesting 388 that F508del CFTR was maximally activated after forskolin stimulation (Fig 4) . This is 389 perhaps surprising when one considers that the gene expression of PDE3 and PDE4D were 390 upregulated in F508del/F508del cells; however, it is worth noting that mRNA abundance 391 may not strictly be proportional to protein expression. In non-corrected F508del/F508del 392 cells, forskolin failed to increase CFTR-dependent I sc and subsequent PDE inhibition also did 393 not activate CFTR, demonstrating the importance of VX-809 and VX-770 therapy for these 394 patients. However, in the presence of PDE inhibitors, VX-770-stimulated I sc was significantly 395 enhanced compared to control cells, suggesting PDE inhibitors can stimulate CFTR after 396 potentiation by VX-770 (Fig. 5) . In R117H/F508del cells, PDE inhibition alone failed to 397 stimulate CFTR-dependent I sc , although rolipram, milrinone + rolipram and RPL554 all 398 increased I sc when cells were prestimulated with forskolin. The lack of effect of milrinone as 399 well as similar I sc stimulations elicited by the PDE4 selective inhibitor rolipram and the dual 400 PDE3/4 inhibitor RPL554 suggests PDE4 inhibition mediates most stimulation of R117H 401 CFTR (Figs. 6-7) . This is consistent with the very low PDE3 gene expression measured in 402 these cells and agrees with other studies which have demonstrated PDE4 activity to be 403 significantly higher than PDE3 activity in HBE cells (16) When responses to submaximal forskolin and apical adenosine were compared in 413 R117H/F508del HBE cells, forskolin stimulated higher CFTR-dependent anion transport than 414 adenosine (Fig 8A) . This parallels earlier findings in Calu-3 cells using the patch-clamp 415
technique (28) showed that CFTR in Calu-3 is strongly activated by the PDE3 inhibitor milrinone and 425 weakly stimulated by rolipram. Similar results were reported by Penmatsa, et al. (48) who 426 found that the PDE3 inhibitor cilostazol stimulated CFTR more strongly than rolipram in 427
Calu-3 cells. They also demonstrated an interaction between CFP-PDE3A and YFP-CFTR in 428 HEK cells using FRET, and co-immunoprecipitated HA-PDE3A with Flag-CFTR. Although 429 some findings remain controversial, they reinforce the importance of PDE activity in 430 regulating local cAMP levels in HBE cells. 431
Considering that RPL554 increases forskolin-stimulated CFTR channel activity, it was 432 interesting to examine its effects in the presence of VX-770 -a clinically prescribed CFTR 433 potentiator. VX-770 binds directly to CFTR to increase channel gating and thus potentiates 434 its activity after stimulation with cAMP agonists (29, 66). We observed that VX-770 further 435 enhanced CFTR activity in cells treated with forskolin and RPL554 (Fig. 9) . Thus, these 436 findings demonstrate CFTR activity can still be increased by CFTR potentiators, even after 437 forskolin and RPL554 stimulation, highlighting that gating limits CFTR activity in the 438 presence of cAMP and that forskolin and RPL554 did not stimulate CFTR to its maximal 439 activity in R117H/ΔF508 cells. However, when cells were stimulated with forskolin and then 440 potentiated with VX-770, subsequent addition of RPL554 failed to further activate CFTR. 441
This indicates that forskolin induced phosphorylation of CFTR is sufficient for a maximal 442 response to VX-770, and once VX-770 has potentiated CFTR further increases in [cAMP] i , 443 due to PDE inhibition have no effect on CFTR activity. Interestingly, when RPL554 was 444 added first followed by VX-770, the net I sc increase was significantly greater than when 445 either agonist was added alone or combined in the reverse order. This implies that combining 446 these two drugs provides the highest level of CFTR stimulation although this will likely 447 depend on the pharmacokinetics of both compounds and require administration of RPL554 448 before VX-770. It is important to note that, in these studies, VX-770 was added acutely so it 449 remains to be seen what would happen in the clinic under chronic dosing conditions. 450 CF airways are chronically inflamed, mediated by high levels of pro-inflammatory cytokines, 451
including 51, 56, 59 ). Therefore, we examined whether CFTR-452 dependent anion transport in response to PDE inhibitors was altered in cells exposed to pro-453 inflammatory cytokines. However, 24 h treatment with TNF-α did not affect the response to 454 PDE inhibition as only PDE4 inhibition stimulated CFTR-dependent I sc in control and TNF-α 455 treated cells (Fig. 10) . However, these data do show that the effects of RPL554 are not 456 compromised by the presence of TNF-α and therefore supports its potential therapeutic use in 457 CF airways. 458
Mucociliary clearance depends on CFTR-driven fluid secretion and ciliary beating therefore 459
we examined the effect of RPL554 on ciliary beat frequency. CBF was increased 460 significantly, consistent with the regulation of CBF by cAMP signalling (Fig. 11) . A similar 461 increase in CBF was observed with roflumilast, which is in agreement with previous findings 462 provide therapeutic benefits to patients carrying at least one R117H allele. The mechanism of 470 action apparently involves exclusively PDE4 and is additive with the effect of 471 therefore it may further enhance CFTR activity in combination with VX-770. RPL554 also 472 increased CBF in well-differentiated HBE cells which again was seemingly mediated by 473 PDE4 inhibition. These findings imply that RPL554 would serve to improve lung function in 474 CF patients by (i) stimulating CFTR-dependent anion transport allowing for mucus hydration 475 and (ii) increasing CBF to enhance mucociliary clearance. Furthermore, CFTR activation 476 causes relaxation of rat and human airway smooth muscle (47, 53, 67) 
